Anokion
Anokion is a biotechnology company focused on antigen-specific immune tolerance to reduce immunogenicity of therapeutic proteins and treat autoimmune and allergic diseases. A spin-off from EPFL, it uses a platform technology that can be applied to many proteins across multiple clinical indications, including autoimmune conditions such as celiac disease, multiple sclerosis, and diabetes. The company is based in Ecublens, Switzerland.
Top Stages
1 past transactions
Kanyos Bio
Acquisition in 2019
Kanyos Bio is focused on creating antigen-specific immune tolerance therapies aimed at treating type 1 diabetes and celiac disease. The company was established to develop disease-modifying treatments that specifically target immune cells responsible for damaging the intestine, while preserving the function of other immune cells. This targeted approach allows for more precise treatment options, potentially leading to improved outcomes for patients. Kanyos Bio's technology has its roots at the École Polytechnique Fédérale Lausanne in Switzerland, and it collaborates with its sister company, Anokion, along with Astellas Pharma to advance its innovations in immunotherapy. Through this collaboration, Kanyos Bio seeks to leverage expertise in immunotechnology and clinical translation to bring effective therapies to market for individuals suffering from these autoimmune conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.